Cost-Effectiveness of Prophylactic Zika Virus Vaccine Cost-Effectiveness of Prophylactic Zika Virus Vaccine


A prophylactic vaccine can help prevent the spread and complications of Zika virus, but how cost-effective is it?Emerging Infectious Diseases

Source: Medscape Today HeadlinesCategory: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Related Links:

by Michel J. Counotte, Christian L. Althaus, Nicola Low, Julien Riou

The 2015–2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread infection, followed by protective immunity. The timing and burden of the next Zika virus outbreak remains unclear. We used an agent-based model to simulate the dynamics of age-specific immunity to ZIKV, and predict th e future age-specific risk using data from Managua, Nicaragua. We also investigated the potential impact of a ZIKV vaccine. Assuming lifelong immunity, the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047. The imbalance in age-s…

MONDAY, Dec. 23, 2019 — An experimental Zika virus vaccine that was given before pregnancy protected monkey fetuses, researchers say.
The Zika DNA vaccine VRC5283 lowered levels of Zika virus in pregnant rhesus macaques and reduced the risk of…


The recent outbreak of Zika virus (ZIKV) in the Americas and its devastating developmental and neurological manifestations has prompted the development of field-based diagnostics that are rapid, reliable, handheld, specific, sensitive, and inexpensive. The gold standard molecular method for lab-based diagnosis of ZIKV, from either patient samples or insect vectors, is reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The method, however, is costly and requires lab-based equipment and expertise, which severely limits its use as a point-of-care (POC) tool in resource-poor settings. Moreover, g…

Source: VirusesCategory: Virology Authors: Tags: Review Source Type: research

Zika virus is primarily transmitted to humans by Aedes mosquitoes.

AbstractHuman challenge trials (HCTs) deliberately infect participants in order to test vaccines and treatments in a controlled setting, rather than enrolling individuals with natural exposure to a disease. HCTs are therefore potentially powerful tools to prepare for future outbreaks of emerging infectious diseases. Yet when an infectious disease is emerging, there is often substantial risk and uncertainty about its complications, and few available interventions, making an HCT ethically complex. In light of the need to consider ethical issues proactively as a part of epidemic preparedness, we use the case of a Zika virus H…

Source: TrialsCategory: Research Source Type: clinical trials

Zika virus (ZIKV) infection of pregnant women is associated with congenital Zika syndrome (CZS) and no vaccine is available, although several are being tested in clinical trials. We tested the efficacy of ZIKV DNA vaccine VRC5283 in a rhesus macaque model of congenital ZIKV infection. Most animal vaccine experiments have a set pathogen exposure several weeks or months after vaccination. In the real world, people encounter pathogens years or decades after vaccination, or may be repeatedly exposed if the virus is endemic. To more accurately mimic how this vaccine would be used, we immunized macaques before conception and the…

Source: Science Translational MedicineCategory: Biomedical Science Authors: Tags: Research Articles Source Type: research


Source: Human Vaccines and ImmunotherapeuticsCategory: Allergy & Immunology Authors: Source Type: research

(University of Texas Medical Branch at Galveston) Researchers from The University of Texas Medical Branch at Galveston showed, for the first time, that a single, higher dose of vaccination to a pregnant mouse safely protects both her and her fetus from the Zika virus.The researchers found that a single, less potent dose was not enough to protect the fetus. The findings are currently available in Nature Communications.

(University of Queensland) A new technology to produce safer ‘hybrid’ viruses at high volumes for use in vaccines and diagnostics for mosquito-borne diseases has been developed at The University of Queensland.Researchers from UQ and QIMR Berghofer Medical Research Institute have exploited the benign characteristics of the Binjari virus – inert to humans – to produce ‘dangerous looking’ mosquito-borne viruses such as Zika and dengue, but which cannot grow in humans or animals.

(American Association for the Advancement of Science) A research team has identified a new species of virus specific to insects that can be engineered to house genes from related viruses that cause diseases such as Zika and yellow fever.

Source link